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Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent transcription factor that regulates
adipocyte differentiation and glucose homeostasis. The transcriptional activity of PPARγ is regulated not only by
ligands but also by post-translational modiﬁcations (PTMs). In this study, we demonstrate that a novel E3 ligase of
PPARγ, tripartite motif-containing 25 (TRIM25), directly induced the ubiquitination of PPARγ, leading to its proteasome-
dependent degradation. During adipocyte differentiation, both TRIM25 mRNA and protein expression signiﬁcantly
decreased and negatively correlated with the expression of PPARγ. The stable expression of TRIM25 reduced PPARγ
protein levels and suppressed adipocyte differentiation in 3T3-L1 cells. In contrast, the speciﬁc knockdown of TRIM25
increased PPARγ protein levels and stimulated adipocyte differentiation. Furthermore, TRIM25-knockout mouse
embryonic ﬁbroblasts (MEFs) exhibited an increased adipocyte differentiation capability compared with wild-type
MEFs. Taken together, these data indicate that TRIM25 is a novel E3 ubiquitin ligase of PPARγ and that TRIM25 is a
novel target for PPARγ-associated metabolic diseases.
Introduction
Adipose tissue plays a pivotal role in storing excess
energy and is a center for energy metabolism1. Excess
body fat is considered one of the major causes of insulin
resistance, dyslipidemia, type 2 diabetes, certain types of
cancer, and cardiovascular disease2. With respect to
obesity, adipocytes exhibit an altered energy homeostasis
status to not only store energy but also to generate and
secrete hormones and cytokines called adipokines1,3. For
instance, the expression of insulin resistance-inducing
adipokines, including tumor necrosis factor-α, inter-
leukin-1, and resistin is increased in the adipose tissue of
obese individuals, whereas the production of the insulin-
sensitizing hormones adiponectin or adipsin is
decreased4. Furthermore, defects in adipocyte differ-
entiation or function increase the probability of metabolic
disorders. Thus, understanding the detailed molecular
mechanisms of adipose tissue biology, especially adipocyte
differentiation, may provide insights for the treatment of
obesity and metabolic syndromes.
Adipocyte differentiation is tightly controlled by a series
of transcription factors. A number of studies have
demonstrated that peroxisome proliferator-activated
receptor gamma (PPARγ) and CCAAT/enhancer bind-
ing proteins (C/EBPs) are the primary regulators of adi-
pogenesis and have been shown to have broad overlap in
their transcriptional targets5,6. Interestingly, C/EBP-α-null
embryonic ﬁbroblast cells fail to undergo adipogenesis,
but this defect can be restored by the overexpression of
PPARγ7,8. Conversely, forced expression of C/EBP-α in
PPARγ-null embryonic ﬁbroblast cells prevents the cells
from differentiating7. These experiments demonstrated
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that PPARγ is the key transcriptional regulator of adipo-
genesis and is both sufﬁcient and necessary for fat cell
differentiation.
The transcriptional activity of PPARγ is well known to
be upregulated by its ligands, such as thiazolidinediones
(TZDs)9. PPARγ speciﬁcally heterodimerizes with reti-
noid X receptor (RXR) and binds DNA repeats of the
sequence AGGTCA (DR1 elements), and the PPARγ/RXR
heterodimer regulates a variety of target genes in different
cells10. In the resting state (in the absence of PPARγ
ligands), PPARγ preferentially binds to nuclear receptor
corepressor 1 (NCOR1) and silencing mediator for reti-
noid and thyroid receptor (SMRT/NCOR2)11. These
complexes recruit chromatin-modifying enzymes such as
histone deacetylases to repress transcription12,13. How-
ever, corepressors become dissociated from PPARγ when
it is activated by ligands. Then, coactivators, such as
steroid receptor coactivators, PPARγ coactivator 1s, his-
tone acyltransferases, and the mediator complexes, are
recruited and interact with PPARγ to promote gene
transcription10,14,15. In addition to ligands, post-
translational modiﬁcations (PTMs), including phosphor-
ylation, SUMOylation, acetylation, and ubiquitination, are
considered as some of the major processes regulating the
transcriptional activity of PPARγ16,17. Phosphorylation of
PPARγ at Ser112 by mitogen-activated protein kinase
suppresses PPARγ transcriptional activity and adipocyte
differentiation18. In contrast, while PPARγ phosphoryla-
tion at Ser273 by cyclin-dependent kinase 5/ERK does not
change its transcriptional activity, this modiﬁcation has
important implications for the treatment of type 2 dia-
betes19,20. SUMOylation of PPARγ at Lys107 blocks its
transcriptional activity, while SUMOylation at Lys395
represses inﬂammatory gene expression by blocking
nuclear factor kappa B (NF-κB) activation13,21,22. PPARγ
is also ubiquitinated and degraded in a proteasome-
dependent manner23,24. Together, these studies have
shown that PTMs of PPARγ are important factors in the
physiological roles of PPARγ. Thus, characterization of
the novel PTMs of PPARγ will provide important insights
into our understanding of the physiological function of
PPARγ with respect to adipogenesis.
Tripartite motif (TRIM) proteins are deﬁned as E3
ubiquitin ligases, as they contain a ring-ﬁnger domain25,26.
To date, more than 77 TRIM proteins have been identi-
ﬁed in humans that are involved in a broad range of
biological processes. TRIM25 (also known as EFP) is a
downstream target of estrogen receptor α27. The expres-
sion of TRIM25 is upregulated in response to estrogen
and is believed to mediate the effects of estrogen with
respect to breast cancer as a primary response gene28. In
addition, TRIM25 induces the ubiquitination of retinoic
acid-inducible gene 1 and regulates host antiviral innate
immunity29. In this study, we report a novel role of
TRIM25 in regulating metabolic pathways by mediating
PPARγ ubiquitination and its proteasome-dependent
degradation, suggesting that TRIM25 may be a potential
therapeutic target in PPARγ-mediated metabolic diseases
such as obesity and type 2 diabetes.
Materials and methods
Cell culture
3T3-L1, HCT116, human embryonic kidney (HEK)-
293T, and HEK-293 cells were obtained from American
Type Culture Collection (Manassas, VA) and cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
fetal bovine serum (Gemini Bio-Products, West Sacra-
mento, CA) and 1% penicillin/streptomycin (Thermo
Fisher Scientiﬁc, Waltham, MA) at 37 °C under a humi-
diﬁed 5% CO2 atmosphere. Adipocyte differentiation was
induced by treating cells with DMEM medium containing
10% fetal bovine serum, 0.5 mM isobutylmethylxanthine,
1 μM dexamethasone, and 850 nM insulin. Two days after
the induction, the inducing medium was replaced with
maintenance DMEM medium containing 10% FBS and
850 nM insulin. Lipid accumulation in the cells was
detected by Oil Red O staining. Wild-type (WT) mouse
embryonic ﬁbroblast cells (MEFs) and TRIM25-knockout
(KO) MEFs were kindly provided by Dr. Kyung-soo Inn
(College of Pharmacy, Kyung Hee University, Korea)29.
All chemicals used for cell culture were obtained from
MilliporeSigma (St. Louis, MO).
Plasmid constructs and RNA interference
The mammalian expression vector for FLAG-epitope
tagged WT PPARγ was described previously19. WT
human TRIM25 and its deletion mutants were kindly
provided by Dr. V. Narry Kim30. siRNAs for TRIM25 #1
(5′-CCTCGACAAGGAAGATAAA-3′) and #2 (5′-GCAT
CTGCTACGGAAGCAT-3′) were purchased from
Shanghai GenePharma (Shanghai, China). HCT116 cells
were transfected with the siRNAs using Lipofectamine
RNAi MAC (Thermo Fisher Scientiﬁc, Waltham, MA).
The sequences used for lentiviral short hairpin RNA
(shRNA) expression vectors (pLKO.1; Dharmacon,
Lafayette, CO) targeting TRIM25 were #1 (5′-TTCC
TCAGTTTGTACTCCAGG-3′) and #2 (5′-ATGATCCA
GATCTATCTTAGG-3′). For lentiviral production, HEK-
293T cells were transfected with 10 µg of the lentiviral
vectors. Following infection of the cells with the viral
vectors, 3T3-L1 cells were selected by incubation with 2
μg/ml puromycin (MilliporeSigma, St. Louis, MO).
Binding assay, immunoprecipitation, and antibodies
Glutathione S-transferase (GST)-fused proteins (PPARγ
domain mutants) immobilized with glutathione-agarose
were incubated with TRIM25-expressing cell lysates for 2
h at 4 °C. Protein complexes were pulled down by
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centrifugation and washed four times with binding buffer.
Precipitates were detected by immunoblotting using anti-
GST or TRIM25 antibodies. For analyzing interactions
between endogenous PPARγ and TRIM25, 3T3-L1 adi-
pocytes were lysed with binding buffer. Cell lysates were
incubated with anti-PPARγ or TRIM25 antibodies and
analyzed by western blotting. HEK-293 cells expressing
PPARγ, TRIM25, or their mutants were lysed in binding
buffer, and total cell lysates were incubated with an anti-
hemagglutinin (HA) antibody at 4 °C. Immunoprecipi-
tants or total cell lysates were analyzed with speciﬁc
antibodies as indicated. The antibodies used in this study
included α-TRIM25, α-PPARγ, α-GST, α-Ub, α-aP2, and
α-adipsin antibodies, which were purchased from Santa
Cruz Biotechnology (Dallas, TX), while α-HA, α-actin, α-
HSP90, and α-adiponectin were purchased from Cell
Signaling Technology (Danvers, MA).
Identiﬁcation of PPARγ-binding complexes
PPARγ-null MEFs7 were cultured in DMEM containing
10% fetal bovine serum. Nuclear extracts were prepared
from PPARγ-null MEFs that stably expressed FLAG-
PPARγWT and were incubated with the immobilized
FLAG M2 agarose gel, which was then washed with
binding buffer and incubated with FLAG peptide to elute
the bound proteins. Immunoprecipitated proteins were
separated by SDS-polyacrylamide gel electrophoresis, and
speciﬁc bands were excised and digested with trypsin. The
digested proteins were then analyzed by reverse-phase
liquid chromatography combined with tandem mass
spectrometry (LC-MS/MS) using a high-resolution hybrid
mass spectrometer (LTQ-Orbitrap; Thermo Scientiﬁc,
Waltham, MA). All MS/MS spectra were searched against
the Uniprot protein sequence database using SequestHT
(Thermo Scientiﬁc, Waltham, MA).
Reporter gene assay
HEK-293 cells were transfected with the pDR-1 luci-
ferase reporter plasmid, PPARγ, RXRα, and pRL-Renilla
using Lipofectamine 2000 (Thermo Fisher Scientiﬁc,
Waltham, MA). Following an overnight transfection, the
cells were treated with rosiglitazone for 24 h. Subse-
quently, the cells were harvested and used to perform
reporter gene assays using a Dual-Luciferase kit (Pro-
mega, Madison, WI). Luciferase activity was normalized
to Renilla activity.
Gene expression analysis
Total RNA was isolated from cells or tissues using
TRIzol reagent (Thermo Fisher Scientiﬁc, Waltham, MA).
RNA was reverse-transcribed using an ABI Reverse
Transcription Kit. Quantitative PCR reactions were per-
formed with SYBR green ﬂuorescent dye on an ABI9300
PCR machine (Supplementary Table 1). Relative mRNA
expression was determined using the ΔΔ−Ct method and
was normalized to tata-binding protein levels.
In vitro ubiquitination assay
FLAG-TRIM25 was transiently expressed in HEK-293
cells, puriﬁed using anti-FLAG M2 afﬁnity gel, and eluted
by adding 3 × FLAG peptide according to the manu-
facturer’s instructions. Recombinant GST-PPARγ protein
was incubated with 200 ng E1 (UBE1, Boston Biochem,
Cambridge, MA), 500 ng E2 (UbcH5c, Boston Biochem,
Cambridge, MA), 10 μg ubiquitin, and 2mM ATP in the
absence and presence of TRIM25WT or TRIM25CS in 60
μl of reaction buffer (40 mM Tris-HCl, pH 7.6, 50 mM
NaCl, and 1mM dithiothreitol) for 1 h at 37 °C. After
incubating, reactions were pulled down with glutathione-
agarose and washed four times with binding buffer, fol-
lowed by western blotting using α-Ub or α-PPARγ anti-
bodies. Reaction mixtures were directly assayed by
western blotting using an α-TRIM25 antibody to assess
TRIM25 self-ubiquitination as a control.
Correlation analysis in human adipose tissues
TPM-normalized RNA-sequencing data from 338 sub-
cutaneous adipose tissue samples were obtained from the
GTEx portal using the sample labels downloaded from
ArrayExpress31. Next, the Pearson correlation coefﬁcient
between TRIM25 and PPARγ within the fat samples was
calculated after removing one outlier sample whose
expression in either gene was more than 5 standard
deviations from the mean. The two genes showed a sig-
niﬁcant negative correlation of −0.248 (p-value 4.14E-6).
Animals
All animal experiments were performed according to
procedures approved by the Ulsan National Institute of
Science and Technology’s Institutional Animal Care and
Use Committee. Five-week-old male C57BL/6J mice
(DBL, Chungbuk, Korea) were fed a high-fat diet (60%
kcal fat, D12492, Research Diets Inc., New Brunswick, NJ)
for 10 weeks. The ob/ob mice used in this study were
purchased from the Jackson Laboratory (Bar Harbor, ME).
Results
TRIM25 interacts with PPARγ
To identify potential PTM modulators of PPARγ, we
performed proteomic analyses of binding complexes
formed with PPARγ. As shown in Fig. 1a, several bands of
potential interest were observed and subjected to LC-MS/
MS. Among the multiple PPARγ-associated proteins
identiﬁed, TRIM25 was of particular interest because it
functions as a ubiquitin E3 ligase and as an ISG15 E3
ligase29,32. TRIM25 has also been reported to mediate
polyubiquitination of the DDX58 N-terminal CARD-like
region, which is crucial for triggering the cytosolic signal
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transduction that leads to the production of interferons in
response to viral infection33. These data led us to inves-
tigate whether TRIM25 plays a physiological role in reg-
ulating both the PTMs and the transcriptional activity of
PPARγ.
To conﬁrm the interaction between TRIM25 and
PPARγ, PPARγ was immunoprecipitated from cultured
adipocytes and TRIM25 was detected by immunoblotting.
As shown in Fig. 1b, PPARγ was observed to interact with
endogenous TRIM25. Structural aspects of the interaction
between TRIM25 and PPARγ were further investigated
in vitro using recombinant PPARγ fragments, including
the A/B region (the transcriptional regulatory region), the
DNA-binding domain/hinge region (DBD/H) and the
ligand-binding domain. As shown in Fig. 1c, TRIM25-
speciﬁcally interacted with the DBD/H domain of PPARγ.
To further identify the speciﬁc region required for
TRIM25 binding to PPARγ, smaller regions of TRIM25
were expressed into HEK-293 cells and
coimmunoprecipitated with TRIM25. As shown in
Fig. 1d, amino acids 81–185 of TRIM25 were necessary
for its interaction with PPARγ.
The E3 ligase activity of TRIM25 is required to decrease
PPARγ protein stability
To elucidate the role of TRIM25 as an E3 ligase, we
generated an E3 ligase-defective TRIM25 mutant by
mutating cysteines 50 and 53 to serine (C50S/C53S,
TRIM25CS), which does not possess E3 ubiquitin ligase
activity34. First, we investigated the effect of TRIM25 on
PPARγ transcriptional activity. A luciferase assay was
performed in HEK-293 cells expressing a peroxisome
proliferator response element-containing luciferase con-
struct. As shown in Fig. 2a, the overexpression of
TRIM25WT decreased PPARγ transcriptional activity.
Importantly, TRIM25CS did not suppress PPARγ tran-
scriptional activity, indicating that the WT E3 ubiquitin
ligase is important for regulating PPARγ transcriptional
Fig. 1 TRIM25 interacts with PPARγ. a Silver staining of PPARγ and its associated proteins. FLAG-tagged PPARγ was puriﬁed using FLAG M2
agarose. b The PPARγ complexes were immunopuriﬁed from adipocytes, and endogenous TRIM25 was detected by western blotting. c GST-fused
fragments of PPARγ (A/B, LBD, DBD/H, and FL) were incubated with cell lysates containing TRIM25. The GST-fragment complexes were analyzed by
western blotting. d HA-tagged deletion mutants of TRIM25 were generated and expressed with PPARγ in HEK-293 cells. From the HA-TRIM25
complexes, PPARγ was analyzed by western blotting
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activity. Consistent with this result, speciﬁc knockdown of
TRIM25 using two different small interfering RNAs
(siRNA #1 and #2) increased PPARγ transcriptional
activity (Fig. 2b). Furthermore, similar effects were
observed when PPARγ was treated with rosiglitazone, a
synthetic PPARγ ligand. Two different TRIM25 siRNAs
increased PPARγ protein levels without altering mRNA
levels (Fig. 2c). Together, these results suggest that
TRIM25 regulates PPARγ protein levels in a manner that
is dependent on its E3 ligase activity.
After establishing that TRIM25 is an E3 ligase that
regulates PPARγ protein levels, we next investigated the
effect of TRIM25 on PPARγ protein stability. While both
TRIM25WT and TRIM25CS interacted with PPARγ,
TRIM25WT induced PPARγ degradation, whereas
TRIM25CS did not (Fig. 2d). Furthermore, an increase in
TRIM25WT expression resulted in decreased PPARγ
protein expression in a dose-dependent manner, which
was not observed for TRIM25CS (Fig. 2e), indicating that
the E3 ligase activity of TRIM25 is involved in PPARγ
degradation. The overexpression of TRIM25 signiﬁcantly
reduced PPARγ protein levels, which was restored by
treating cells with MG132, a speciﬁc proteasome inhibitor
(Fig. 2f). Together, these results strongly suggest that
proteasomal degradation of PPARγ is mediated by
TRIM25.
Next, we used a cycloheximide chase assay to measure
the half-life of PPARγ in cells that overexpressed or were
downregulated for TRIM25. As shown in Fig. 3a, com-
pared with control cells, the half-life of PPARγ was sig-
niﬁcantly reduced by the overexpression of TRIM25WT
but not TRIM25CS. In addition, the speciﬁc knockdown of
Fig. 2 TRIM25 degrades PPARγ through the proteasomal pathway. a, b TRIM25 represses the transcriptional activity of PPARγ. HEK-293 cells were
transfected with TRIM25WT and TRIM25CS with PPARγ (a) or siRNAs against TRIM25 (#1 and #2) with PPARγ (b) with or without rosiglitazone. Cells were
analyzed with a luminometer (n= 3). c The TRIM25 protein level was increased by TRIM25 siRNAs in HCT116 cells. The PPARγ and TRIM25 protein
levels were analyzed by western blotting, and their mRNA levels were analyzed by real-time quantitative PCR (RT-qPCR) (n= 3). d HEK-293 cells were
transfected with PPARγ, TRIM25WT, or TRIM25CS. The interaction between TRIM25 and PPARγ was analyzed by western blotting. Relative PPARγ
protein levels were measured using ImageJ (bottom graphs). e HEK-293 cells were transfected with TRIM25WT or TRIM25CS with PPARγ in dose-
dependent manner. Indicated proteins were measured by western blotting. f HEK-293 cells were transfected with TRIM25WT with PPARγ in dose-
dependent manner with or without MG132 (10 μM for 6 h). The indicated proteins were measured by western blotting. All error bars shown are the s.
e.m. (*p < 0.05, **p < 0.01, ***p < 0.001)
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TRIM25 could stabilize PPARγ, suggesting that TRIM25
is a key regulator of PPARγ protein stability (Fig. 3b).
TRIM25 is an E3 ligase that mediates the ubiquitination of
PPARγ
Next, we performed a ubiquitination analysis to further
assess whether TRIM25 functions as a speciﬁc E3 ligase of
PPARγ. We used a retroviral system to generate 3T3-L1
cell lines that stably overexpressed TRIM25WT or
TRIM25CS or carried empty vector (control cell line), and
the cells were fully differentiated into adipocytes. Endo-
genous PPARγ from cultured adipocytes was immuno-
precipitated to assess the ubiquitination of PPARγ by
western blotting (Fig. 4a). Although the PPARγ protein
levels were decreased in cells expressing TRIM25WT,
TRIM25WT expression resulted in increased PPARγ ubi-
quitination when cells were pretreated with MG132,
which was not observed following TRIM25CS expression.
Consistent with these results, transiently expressed
TRIM25WT enhanced PPARγ ubiquitination compared
with the TRIM25CS mutant in HEK-293 cells (Fig. 4b). To
further conﬁrm the direct effect of TRIM25 on the ubi-
quitination of PPARγ, we performed an in vitro ubiqui-
tination assay using puriﬁed TRIM25 and PPARγ. As
expected, TRIM25 induced the ubiquitination of recom-
binant PPARγ, while TRIM25CS did not (Fig. 4c). These
results suggest that PPARγ is a substrate of TRIM25.
TRIM25 is negatively correlated with PPARγ
In the present study, our results demonstrated that
TRIM25 regulates PPARγ protein stability. Thus, we next
investigated the physiological role of TRIM25 in adipocyte
differentiation. First, we examined the physiological rele-
vance of TRIM25 and PPARγ during adipocyte differ-
entiation. Western blot and real-time PCR analyses
revealed that TRIM25 was expressed in pre-adipocytes
and that its expression was signiﬁcantly decreased during
adipogenesis (Fig. 5a, b). In contrast with TRIM25
expression, the expression of PPARγ and adipogenic
marker genes, including aP2 and adiponectin, were sig-
niﬁcantly increased, indicating that TRIM25 expression is
negatively correlated with that of PPARγ. Next, we mea-
sured TRIM25 expression in adipose tissue from high-fat-
diet (HFD)-induced obesity model mice and genetically
induced obesity model mice (ob/ob). As shown in Fig. 5c,
d, TRIM25 expression was signiﬁcantly downregulated in
adipose tissue from both HFD and ob/ob mice compared
with control mice, whereas PPARγ expression was dra-
matically upregulated. To examine whether the correla-
tion between TRIM25 and PPARγ expression in adipose
tissue is relevant in humans, we used RNA-sequencing
data of 338 human adipose tissue samples from the
Genotype-Tissue Expression (GTEx) project to analyze
the correlation between TRIM25 and PPARγ gene
expression35,36. As shown in Fig. 5e, the expression of
TRIM25 was signiﬁcantly negative correlated with that of
PPARγ. Taken together, these results suggest that the
expression of TRIM25 is inversely correlated with that of
PPARγ in both mice and humans.
TRIM25 suppresses adipocyte differentiation
PPARγ is both necessary and sufﬁcient for adipogenesis,
and alterations in PPARγ activity affect adipogenesis.
Consistent with the observed TRIM25-mediated down-
regulation of PPARγ stability, when TRIM25WT was
expressed in differentiating 3T3-L1 cells, triglyceride
accumulation was suppressed, as conﬁrmed by Oil Red O
staining (Fig. 6a). Furthermore, the protein and mRNA
expression levels of adipocyte-selective genes, including
aP2, C/EBP-α, adiponectin, adipsin, glucose transporter-4
Fig. 3 TRIM25 destabilizes PPARγ. HCT116 cells were transfected with TRIM25WT and TRIM25CS (a) or siRNAs against TRIM25 (#1 and #2) (b) in the
presence or absence of CHX (50 μg/ml for the indicated time). The indicated proteins were measured by western blotting. Relative PPARγ protein
levels were measured using ImageJ (bottom graphs)
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(GLUT4), and LPL were also reduced (Fig. 6b, c). How-
ever, the TRIM25CS mutant did not alter the expression of
adipogenic markers. In addition, the speciﬁc knockdown
of TRIM25 using a lentivirus expressing a shRNA tar-
geting TRIM25 enhanced adipocyte differentiation
(Fig. 6d) and the expression of adipocyte-speciﬁc proteins
and genes compared with that of the control (Fig. 6e, f).
To further conﬁrm the effect of TRIM25 on adipogen-
esis, we used WT and TRIM25 KOMEFs. Compared with
WT MEFs, KO MEFs exhibited dramatically enhanced
lipid accumulation (Fig. 7a). Furthermore, the expression
of adipogenic markers was signiﬁcantly increased in KO
MEFs compared with WT MEFs (Fig. 7b, c). Taken
together, these results suggest that TRIM25 plays a key
role in the regulation of PPARγ-dependent adipogenic
processes.
Discussion
Adipose tissue is the center of systemic metabolic reg-
ulation in rodents and humans. The dysregulation of
adipocyte differentiation and/or physiological function
results in metabolic disorders such as type 2 diabetes37,38.
As PPARγ functions as a master regulator of fat cell dif-
ferentiation and glucose/lipid metabolism, understanding
the mechanisms of PPARγ regulation is crucial for com-
bating metabolic disorders. In this study, we demon-
strated that the E3 ubiquitin ligase TRIM25 regulates the
protein stability of PPARγ, inhibiting adipogenesis in both
3T3-L1 cells and MEFs. Several lines of evidence support
this conclusion. First, TRIM25 directly interacts with
PPARγ and increases ubiquitin- and proteasome-
mediated PPARγ degradation. Second, speciﬁc knock-
down of TRIM25 dramatically increases adipocyte
differentiation. Finally, the expression of TRIM25 is
inversely correlated with that of PPARγ in adipose tissue
in both mice and humans.
Although numerous studies have reported on the reg-
ulation of PPARγ expression at the transcriptional level,
the regulation of PPARγ expression at the protein level
has been poorly studied. Recently, multiple lines of evi-
dence have suggested that PPARγ is regulated by PTMs,
including phosphorylation, SUMOylation, and
Fig. 4 TRIM25 mediates the ubiquitination of PPARγ through its E3 ligase activity. a 3T3-L1 cells were stably expressed with TRIM25WT or
TRIM25CS and differentiated for 6 days. Cells were treated with MG132 for 6 h. Cell lysates were incubated with an α-PPARγ antibody, and
ubiquitination of PPARγ was analyzed by western blotting. b HEK-293 cells were transfected with TRIM25WT or TRIM25CS. Cell lysates were incubated
with an α-FLAG antibody, and ubiquitination of PPARγ was analyzed by western blotting. c Ubiquitination of PPARγ by TRIM25 in vitro. Puriﬁed GST-
tagged PPARγ was incubated with E1, E2, ubiquitin (Ub), TRIM25WT, or TRIM25CS in the absence and presence of ATP as indicated. Ubiquitination of
PPARγ was analyzed by western blotting using the indicated antibodies
Lee et al. Experimental & Molecular Medicine  (2018) 50:135 Page 7 of 11
Ofﬁcial journal of the Korean Society for Biochemistry and Molecular Biology
ubiquitination17,24. In particular, the polyubiquitination of
PPARγ is crucial for regulating both its expression and
transcriptional activity. MKRN1, an E3 ligase of PPARγ,
was observed to induce PPARγ ubiquitination and its
proteasome-mediated degradation39. However, the ubi-
quitination of PPARγ does not always increase its degra-
dation. In a report by Kilroy et al.40, TZDs increased the
expression of E3 ligase, Siah2, and Siah2, which are
required for adipogenesis by ubiquitinating PPARγ. In
addition, NEDD4, an E3 ubiquitin ligase, interacts with
and ubiquitinates PPARγ, which results in increased
PPARγ protein stability by inhibiting its proteosomal
degradation41. In this study, we demonstrated that the
ubiquitination of PPARγ by a novel E3 ligase, TRIM25,
promoted PPARγ proteosomal degradation and sup-
pressed adipogenesis. These results suggest that there are
several distinct pathways for ubiquitin-mediated PPARγ
regulation and that each E3 ligase regulates PPARγ
stability in response to different cellular signals or con-
ditions in adipocytes.
Recent reports have suggested that the protein stabi-
lity of PPARγ can be regulated by phosphorylation.
Keshet et al.42 demonstrated that c-Abl-mediated tyr-
osine phosphorylation of PPARγ increases its accumu-
lation. In addition, epidermal growth factor receptor has
been suggested to induce PPARγ phosphorylation,
which could lead to MDM2 E3 ubiquitin ligase-
mediated PPARγ ubiquitination and degradation43,44.
Thus, we tested whether known phosphorylation sites of
PPARγ could modulate TRIM25-mediated PPARγ ubi-
quitination and degradation. TRIM25 reduced the sta-
bility of the phospho-defective mutants PPARγ S112A
and PPARγ S273A (data not shown)18,19. Interestingly,
phosphorylation at Y78 of PPARγ dramatically sup-
pressed TRIM25-mediated PPARγ ubiquitination and
increased PPARγ accumulation (Supplementary
Fig. 5 Negative correlation between TRIM25 and PPARγ expression both in mice and humans. a Immunoblot analysis of TRIM25, PPARγ, and
adipogenic markers during 3T3-L1 cell differentiation. Relative TRIM25 protein levels were measured using ImageJ (bottom graphs). b Real-time
quantitative PCR analysis of the mRNA expression of TRIM25, PPARγ, and adipogenic markers during 3T3-L1 cell differentiation. c Immunoblot analysis
of TRIM25 and PPARγ in white adipose tissue (WAT) of normal chow-fed (NC) vs. high-fat-fed (HFD) mice. d Immunoblot analysis of TRIM25 and
PPARγ in WAT of control vs. ob/ob mice. Relative TRIM25 and PPARγ protein levels were measured using ImageJ (right graphs). e Pearson correlation
coefﬁcients between TRIM25 and PPARγ levels within human subcutaneous fat samples were calculated. All error bars shown are the s.e.m. (*p < 0.05,
**p < 0.01, ***p < 0.001)
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Figure 1). Tyrosine phosphorylation of PPARγ at Y78 is
induced by the c-Abl or c-Src kinases, both of which are
required for fat cell differentiation42,45,46. Therefore, it is
likely that the modulation of PPARγ phosphorylation at
Y78 is an important regulatory mechanism for its pro-
tein stability and fat cell differentiation activity. Further
mechanistic studies on the role of Y78 phosphorylation
in TRIM25-mediated PPARγ regulation should be
conducted in the future.
In this study, we demonstrated that TRIM25 binds to
PPARγ in adipocytes and that the expression of TRIM25
and PPARγ is inversely correlated in adipocytes in both
mice and humans (Fig. 5). Furthermore, we demonstrated
the expression of TRIM25 during adipogenic processes,
and both TRIM25 gene and the protein levels were
transiently reduced after inducing adipocyte differentia-
tion (Fig. 5). The exact molecular mechanism of how the
expression of TRIM25 is reduced during adipogenic dif-
ferentiation process remains unclear. However, we believe
that the decrease in TRIM25-mediated degradation of
PPARγ during differentiation, in combination with the
increase of PPARγ gene expression and increased activity
of PPARγ, directly induces the expression of PPARγ itself
or C/EBPα during differentiation. In addition to adipo-
cytes, TRIM25 and PPARγ are also expressed in different
cells and tissues, especially tumors47–49. Multiple lines of
evidence suggest that PPARγ acts as a tumor suppressor
because it plays a role in inﬂammation and glucose
metabolism in cancer. The overexpression of PPARγ
suppresses cell survival by inhibiting cell proliferation and
tumor growth50. In contrast, the silencing of PPARγ in
cancer has the opposite effect on the activation of the
cancer survival pathway51. TRIM25 has also been linked
to several cancers. In particular, TRIM25 is overexpressed
in breast, colorectal, and lung cancers, while PPARγ is
downregulated in these cancers compared with normal
tissues52–54. These results suggest that TRIM25 may act
as a crucial regulator of PPARγ in different types of
tumors. Although further studies are needed to elucidate
the molecular relationship between TRIM25 and PPARγ
in tumor progression, our results extend our knowledge
regarding the regulation of PPARγ and potential targets
for the development of novel therapeutic approaches
targeting obesity and metabolic diseases.
Fig. 6 TRIM25 suppresses adipocyte differentiation in 3T3-L1 cells. Stably expression of TRIM25WT and TRIM25CS (a–c) or shRNAs (#1 and #2) for
TRIM25 (d–f) in 3T3-L1 pre-adipocytes was induced for 6 days. a, d Differentiated cells were stained by Oil Red O. b, e The protein expression of
TRIM25, PPARγ, and adipogenic markers was analyzed by western blotting. c, f The mRNA expression of adipogenic markers was analyzed by real-
time quantitative PCR. All error bars shown are the s.e.m. (*p < 0.05, **p < 0.01, ***p < 0.001)
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